About Affymetrix

Stock Quote

Security
AFFX (Common Stock)
$8.67
+2.24%
Current Day's High
8.73
Current Day's Low
8.49
Current Day's Volume
353,364
Last Trade
Aug 29 14 4:00 p.m. ET
Exchange
NASDAQ GS

The stock price performance shown on the quote above is not necessarily indicative of future price performance

Bookmark and Share

2014 Press Releases

Keyword Search
 
All Releases |2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005
TitleDate
Affymetrix Reports Second Quarter 2014 Operating Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 31, 2014-- Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the second quarter of 2014. Results for the three months ended June 30, 2014: Total revenue was $85.4 million, compared to $79.5 million in second quarter of 2013. Total revenue grew by 7.5% over the second quarter of 2013. Product revenue was $75.9 million compared to $74.2 ... 
07/31/14
Affymetrix to Report Second Quarter 2014 Operating Results on Thursday July 31, 2014
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 7, 2014-- Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will report operating results for the second quarter of 2014 after market close on Thursday July 31, 2014. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the Investor Relations section of the company’s website at www.affymetrix.com. Alternatively, investors and other i... 
07/07/14
Affymetrix Announces Recipients of Its 2014 Tumor Profiling Grant Award to Support Translational Cancer Research
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun. 18, 2014-- Affymetrix (Nasdaq:AFFX) announces the three recipients who have been awarded its 2014 Affymetrix Tumor Profiling Grant. The goal of this grant program is to support translational cancer research in discovery and analytical validation of biomarkers that may address current unmet clinical needs in cancer diagnosis, prognosis, and treatment. Research projects considered for the grant use the appr... 
06/18/14
Affymetrix and BioDiscovery Launch a Tailored Copy Number Analysis Software Solution for Cancer Research
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun. 5, 2014-- Affymetrix (Nasdaq: AFFX) and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix’ genetic analysis platforms in cancer research, including CytoScan® Cytogenetics Suite and OncoScan® FFPE Assay Kit. “CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of... 
06/05/14
Affymetrix and Leica Biosystems Announce the Launch of Fully Automated RNA in situ Hybridization Assays
ViewRNATM eZ Assays, fully automated on the Leica BOND RX, offer remarkable sensitivity and specificity of staining for coding and non-coding markers in an easy-to-use, fully automated format. SANTA CLARA, Calif.--(BUSINESS WIRE)--May 8, 2014-- Affymetrix, Inc. (NASDAQ:AFFX) and Leica Biosystems announce the launch of Affymetrix’ fully automated RNA in situ hybridization assays ViewRNATM eZ Assays on the Leica BOND RX staining pl... 
05/08/14
Affymetrix Reports First Quarter 2014 Operating Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--May 1, 2014-- Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the first quarter of 2014. Results for the three months ended March 31, 2014: Total revenue was $83.0 million, compared to $77.9 million in first quarter of 2013. The first quarter of 2013 included $1.5 million of revenue associated with a product line which was divested in the fourth quarter... 
05/01/14
Affymetrix to Report First Quarter 2014 Operating Results on Thursday May 1st, 2014
SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 2, 2014-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it will report operating results for the first quarter of 2014 after market close on Thursday May 1, 2014. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the Investor Relations section of the company’s website at www.affymetrix.com. Alternatively, investors and other int... 
04/02/14
Affymetrix Reports Fourth Quarter and Fiscal Year 2013 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 5, 2014-- Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the three and twelve months ended December 31, 2013. Results for the three months ended December 31, 2013: Total revenue was $92.6 million, which included revenue from eBioscience of $20.5 million. Product revenue was $82.1 million, as compared to product revenue for the four... 
02/05/14
Affymetrix Receives FDA Clearance of First-of-its-kind Postnatal Test for Developmental Delays and Intellectual Disabilities in Children
CytoScan® Dx Assay represents a technology leap over traditional postnatal genetic tests and significantly improves diagnostic capability SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 21, 2014-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan® Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants ... 
01/21/14
University of Bristol Collaborates with Affymetrix on Genotyping Arrays for Guaranteed Sustainability of Wheat Production
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 13, 2014-- Affymetrix, Inc. (NASDAQ: AFFX) and University of Bristol, Bristol, UK, announced today that they have collaboratively designed a wheat genotyping array and analyzed data from experiments as part of an effort to understand wheat genetics and breeding with a goal of ensuring guaranteed sustainable production. Axiom® Wheat Genotyping Array (Axiom Wheat Array), consisting of 817,000... 
01/13/14
— Affymetrix Announces Preliminary Fourth Quarter 2013 Revenue of Approximately $91 Million —
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 7, 2014-- Affymetrix, Inc., (NASDAQ: AFFX) today announced that based on preliminary, unaudited financial data, the Company expects total revenue for the fourth quarter of 2013 will be approximately $91 million, including a one-time licensing payment of $5.3 million from a diagnostic partner. For fiscal 2013, the Company expects total revenue of approximately $329 million. "In 2013 we executed effectively against our three phase strategic plan and we ... 
01/07/14


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.


Back to Top >